Studies have found that GLP-1 receptor is not only expressed in islet cells, but also widely distributed in brain, lung, gastrointestinal tract, kidney, liver, heart and other organs in the body
A liverfirst approach includes: Confirming liver involvement with imaging and fibrosis assessments Evaluating comorbid metabolic conditions Tailoring lifestyle guidance to support hepatic outcomes Initiating GLP1s where appropriate for both metabolic and liver health Monitoring ALT/AST and noninvasive fibrosis scores alongside traditional outcomes Even in patients with normal A1C or lean body type, these therapies can play a role
But starting treatment can still come with some unexpected twists, especially if you're not sure what to expect
Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, et al: Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model